← Back to Clinical Trials
Recruiting NCT06993922

NCT06993922 Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06993922
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Dexmedetomidine
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-05-29
Primary Completion 2025-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Scalp blockScalp block + Dexmedetomidine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-05-29 with a primary completion date of 2025-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.

Eligibility Criteria

Inclusion Criteria: * Age from 18 to 65 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I or II. * Undergoing supratentorial elective planned craniotomies. Exclusion Criteria: * Patients refusal. * History of known allergy to the used local anesthetic or dexmedetomidine. * Bleeding disorders. * Evidence of local infection at the site of injection. * Emergency craniotomy. * Psychotic disorder. * Patients who will not be extubated in the operating room after surgery.

Contact & Investigator

Central Contact

Omar A Khiralla, MBBCH

✉ Omar-Ahmed@med.asu.edu.eg

📞 00201095281838

Frequently Asked Questions

Who can join the NCT06993922 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Dexmedetomidine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06993922 currently recruiting?

Yes, NCT06993922 is actively recruiting participants. Contact the research team at Omar-Ahmed@med.asu.edu.eg for enrollment information.

Where is the NCT06993922 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06993922 clinical trial?

NCT06993922 is sponsored by Ain Shams University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology